Assessing Exelixis (EXEL) Valuation After Recent Share Price Pullback And Long Term Gains

Simply Wall St.01-18

AdvertisementWhy Exelixis (EXEL) Is On Investors’ Radar Today Exelixis (EXEL) has drawn attention after recent trading left the shares at a last close of US$43.96, prompting investors to reassess the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604992934?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119","is_english":true,"pubTime":"2026-01-18 04:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604992934","market":"nz","top_or_hot":-1,"title":"Assessing Exelixis (EXEL) Valuation After Recent Share Price Pullback And Long Term Gains","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Exelixis (EXEL) Is On Investors’ Radar Today Exelixis (EXEL) has drawn attention after recent trading left the shares at a last close of US$43.96, prompting investors to reassess the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/assessing-exelixis-exel-valuation-after-recent-share-price-p\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Exelixis (EXEL) Valuation After Recent Share Price Pullback And Long Term Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Exelixis (EXEL) Valuation After Recent Share Price Pullback And Long Term Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-18 04:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/assessing-exelixis-exel-valuation-after-recent-share-price-p><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Exelixis (EXEL) Is On Investors’ Radar Today Exelixis (EXEL) has drawn attention after recent trading left the shares at a last close of US$43.96, prompting investors to reassess the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/assessing-exelixis-exel-valuation-after-recent-share-price-p\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/assessing-exelixis-exel-valuation-after-recent-share-price-p","article_id":"2604992934","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/assessing-exelixis-exel-valuation-after-recent-share-price-p","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604992934","pubTimestamp":1768681714,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Exelixis (EXEL) Is On Investors’ Radar Today\nExelixis (EXEL) has drawn attention after recent trading left the shares at a last close of US$43.96, prompting investors to reassess the oncology company’s profile and the value they place on its pipeline.\nSee our latest analysis for Exelixis.\nDespite a 3.26% 1 day share price decline and a flat week, Exelixis has a 4.67% 30 day share price return and a 21.44% 1 year total shareholder return, while the 3 year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EXEL":"伊克力西斯","BK4532":"文艺复兴科技持仓"},"translate_title":"在近期股价回调和长期上涨后评估Exelixis(EXEL)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1.5},"content_text":"AdvertisementWhy Exelixis (EXEL) Is On Investors’ Radar Today Exelixis (EXEL) has drawn attention after recent trading left the shares at a last close of US$43.96, prompting investors to reassess the oncology company’s profile and the value they place on its pipeline. See our latest analysis for Exelixis. Despite a 3.26% 1 day share price decline and a flat week, Exelixis has a 4.67% 30 day share price return and a 21.44% 1 year total shareholder return, while the 3 year total shareholder return of 162.76% signals strong longer term momentum. If Exelixis has you looking closer at oncology and biotech, it could be a good moment to scan the wider sector using our healthcare stocks. With the shares near US$44 and trading at only a small discount to the average analyst price target of US$45.61, the key question is whether Exelixis remains a misunderstood value or if the market is already incorporating expectations of future growth into the price. Most Popular Narrative: 2.3% Undervalued With Exelixis last closing at US$43.96 and the most followed narrative pointing to a fair value of about US$45, the gap is narrow but meaningful enough for investors to want to understand what is driving that view.  The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships, which has the potential to improve operating leverage and net margins over time as the product portfolio scales.  Read the complete narrative. Curious how steady revenue growth, rising margins and a lower future P/E are combined to support that fair value? The narrative leans on detailed forecasts for sales, profitability and share count that are not obvious from headline numbers alone. If you want to see how those moving parts connect to the valuation call, the full narrative lays it out step by step. Result: Fair Value of $45 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh the heavy reliance on CABOMETYX, as well as the possibility that key late stage trials or new launches fail to deliver as analysts expect. Find out about the key risks to this Exelixis narrative.  Build Your Own Exelixis Narrative If you look at the numbers and come to a different view, or just prefer to test your own assumptions, you can build a fresh narrative in a few minutes using Do it your way. A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If Exelixis has sharpened your interest in healthcare and growth stories, do not stop here, fresh opportunities often show up where you least expect them.  Spot potential value with momentum by checking out these 863 undervalued stocks based on cash flows that fit the kind of price and quality profile you want to keep on your radar. Jump ahead of the next big theme by scanning these 24 AI penny stocks that are tied to powerful trends in automation, data and machine learning. Strengthen your income watchlist by reviewing these 12 dividend stocks with yields > 3% that might suit a returns focused approach built around regular payouts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Exelixis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604992934","isCrawlerRequest":true}